Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.

Giordano, A.; Giuliano, Mario; Hsu, Li‐Han; Handy, Beverly Carol; Ueno, NT; Andreopoulou, Eleni; Alvarez, R. H.; Hortobágyi, Gabriel N.; Cristofanilli, Massimo

doi:10.1200/jco.2010.28.15_suppl.1000

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…recent data suggest limited prognostic value of CtCs in mBC patients treated with anti angiogenic therapy, 95,96 or in patients pretreated with anti-Her2 therapy. 97 recent data confirmed the prognostic value of CtCs in early-stage breast cancer. the majority of studies used >1 CtCs as a cut off to discriminate prognostic groups because of lower detection rates of CtCs compared with mBC.…”

Section: Review Criteriamentioning

confidence: 51%

Molecular mechanisms of metastasis in breast cancer—clinical applications

2010

View full text Add to dashboard Cite

The metastatic cascade is a series of biological processes that enable the movement of tumor cells from the primary site to a distant location and the establishment of a new cancer growth. Circulating tumor cells (CTCs) have a crucial role in tumor dissemination. The role of CTCs in treatment failure and disease progression can be explained by their relation to biological processes, including the epithelial-to-mesenchymal transition and 'self seeding', defined as reinfiltration of the primary tumor or established metastasis by more aggressive CTCs. CTCs are a unique and heterogeneous cell population with established prognostic and predictive value in certain clinical situations. The possibility of collecting sequential blood samples for real-time monitoring of systemic-therapy efficacy presents new possibilities to evaluate targeted therapies based on the genomic profiling of CTCs and to improve the clinical management of patients by personalized therapy. Interruption of the metastatic cascade via the targeting of CTCs might be a promising therapeutic strategy.

show abstract

Section: Review Criteriamentioning

confidence: 51%

Molecular mechanisms of metastasis in breast cancer—clinical applications

2010

View full text Add to dashboard Cite

show abstract

“…most of the patients had multiple sites of metastasis and only three visceral and four bone/soft tissue). Correlations of CTCs detection and prognosis with molecular subtypes and site of metastasis was published in retrospective Annals of Oncology original article study Giordano et al [35]. CTCs strongly predict survival in different immunohistochemical subtypes of MBC, except for the HR2/HER-2 (hormone receptor/human epidermal growth factor receptor-2) and CTCs are a strong prognostic factor in patients without or with metastatic visceral involvement [35].…”

Section: Discussionmentioning

confidence: 99%

Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts

Saldova

Reuben²,

Hamid

et al. 2011

Annals of Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Prognostic value of CTCs has been demonstrated in metastatic breast cancer by many studies [18,89,90]. Since the Food and Drug Administration approval of CellSearch System (Menarini Silicon Biosystems, Inc, Bologna, Italy) as the only device suitable for CTC quantification in the clinics, many efforts were undertaken to asses CTC utility in the monitoring and treatment of women with MBC.…”

Section: Advanced Breast Cancer; Prognostic Value Programs and Trialsmentioning

confidence: 99%

Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value

Fabisiewicz

Szostakowska-Rodzoś

Żaczek

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer metastasis is the leading cause of cancer deaths in women and is difficult to combat due to the long periods in which disseminated cells retain a potential to be re-activated and start the relapse. Assessing the number and molecular profile of circulating tumor cells (CTCs) in breast cancer patients, especially in early breast cancer, should help in identifying the possibility of relapse in time for therapeutic intervention to prevent or delay recurrence. While metastatic breast cancer is considered incurable, molecular analysis of CTCs still have a potential to define particular susceptibilities of the cells representing the current tumor burden, which may differ considerably from the cells of the primary tumor, and offer more tailored therapy to the patients. In this review we inspect the routes to metastasis and how they can be linked to specific features of CTCs, how CTC analysis may be used in therapy, and what is the current status of the research and efforts to include CTC analysis in clinical practice.There are two main hypotheses describing cancer dissemination: linear progression, according to which, metastatic potential is gained gradually, and the whole process proceeds in steps and needs time, and parallel progression, according to which dissemination takes place early on, even before clinical manifestation of the tumor [6,7] (Figure 1). In the linear progression model, the evolving primary tumor gives rise to metastases due to increasingly aggressive and invasive phenotypes of the subclones of tumor cells. This model is in agreement with the postulated role of the epithelial-to-mesenchymal transition (EMT) in cancer and assumes active degradation of the stroma and migration into blood vessels by the motile, invasive single cells that broke loose from the epithelial monolayer. In contrast to that, parallel progression postulates intravasation by passive shedding, which may take place shortly after the angiogenic switch, occurring during the early, pre-invasive stage of tumor development [8,9].

show abstract

Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.

Cited by 8 publications

References 0 publications

Molecular mechanisms of metastasis in breast cancer—clinical applications

Molecular mechanisms of metastasis in breast cancer—clinical applications

Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts

Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value

Contact Info

Product

Resources

About